

WHAT YOU SHOULD KNOW ABOUT ADULT GROWTH HORMONE DEFICIENCY (AGHD)

AGHD is an underdiagnosed disorder commonly associated with pathology of the hypothalamus or pituitary. Patients with AGHD tend to live with a poor quality of life and often present with other comorbidities.¹

WHY IS GROWTH HORMONE (GH) IMPORTANT IN ADULTS?

GH is a metabolic hormone that regulates homeostasis of¹:

PROTEINS

LIPIDS

CARBOHYDRATES

GH is required for regular growth, development, and maintenance of the body and mind.

SYMPTOMS OF AGHD²⁻⁴

Brain


Decreased psychological well-being
Social isolation
Sexual dysfunction⁵

Muscle

Abnormal heart function
Decreased lean muscle
Reduced muscle strength
Increase in inflammatory markers⁶

Metabolism

Increase in LDL cholesterol
Increased abdominal fat
Decreased bone mineral density
Insulin resistance



AGHD USUALLY GOES UNDIAGNOSED

BECAUSE IT OFTEN REQUIRES TESTING BEYOND PHYSICAL EXAMINATION AND TYPICAL BLOOD WORK.^{7,8}

2 TYPES OF AGHD^{3,9}

CONGENITAL



People with this form of GHD are born with it
Results from genetic mutations or from structural defects in the brain

ACQUIRED



People with this form of GHD are diagnosed later in life
Results from surgery, trauma, infection, radiation therapy, or tumor growth within the brain

IN THE UNITED STATES,¹⁰

>50,000

adults have an AGHD diagnosis

≈6000

new cases of AGHD are reported annually

AGHD TYPICALLY RESULTS IN ABNORMALITIES OF^{2,11}

- Body composition
- Body fluids
- Muscle and bone growth
- Mental function
- Heart function

POTENTIAL CAUSES OF AGHD¹²

HYPOTHALAMIC DISEASES

Mass lesions—benign (craniopharyngiomas) and malignant tumors (metastatic from lung, breast, etc.)
Radiation—for CNS and nasopharyngeal malignancies
Infiltrative lesions—sarcoidosis, Langerhans cell histiocytosis
Infections—tuberculous meningitis
Other—traumatic brain injury, stroke

PITUITARY DISEASES

Mass lesions—pituitary adenomas, other benign tumors, cysts
Pituitary surgery
Pituitary radiation
Infiltrative lesions—hypophysitis, hemochromatosis
Infection/abscess
Infarction—Sheehan syndrome
Apoplexy
Genetic mutations
Empty sella syndrome

DIAGNOSING AGHD

Measuring insulin-like growth factor 1 (IGF-1) is a standard assessment of GH function; however, 50% of people with AGHD have IGF-1 levels within the normal reference range. If IGF-1 is within normal range, the most appropriate stimulatory test should be administered to rule out or confirm diagnosis of AGHD.^{8,13}

Remind your patients who are experiencing symptoms common with AGHD about the importance of getting tested, and talk to them about the different testing options available.

A SIMPLE TEST CAN HELP CONFIRM DIAGNOSIS OF AGHD.

References: **1.** Ayuk J, Sheppard MC. Growth hormone and its disorders. *Postgrad Med J.* 2006;82(963):24-30. **2.** Monson JP, Brooke AM, Akker S. Adult growth hormone deficiency. In: Feingold KR, Anawalt B, Boyce A, et al, eds. *Endotext.* South Dartmouth, MA: MDText.com, Inc.; 2015. **3.** Gupta V. Adult growth hormone deficiency. *Indian J Endocrinol Metab.* 2011;15(suppl 3):S197-S202. **4.** Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. *N Engl J Med.* 2019;380(26):2551-2562. **5.** Cuesta M, Hannon MJ, Crowley, RK, et al. Symptoms of gonadal dysfunction are more predictive of hypopituitarism than nonspecific symptoms in screening for pituitary dysfunction following moderate or severe traumatic brain injury. *Clin Endocrinol (Oxf).* 2016;84(1):92-98. **6.** Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH—an update. *J Clin Endocrinol Metab.* 2014;99(1):18-29. **7.** Yuen KCJ, Tritos NA, Samson SL, Hoffman AR, Katznelson L. American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency. *Endocr Pract.* 2016;22(10):1235-1244. **8.** Glynn N, Agha A. Diagnosing growth hormone deficiency in adults. *Int J Endocrinol.* 2012;2012:972617. doi:10.1155/2012/972617. **9.** Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; for The Endocrine Society's Clinical Guidelines Subcommittee. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2006;91(5):1621-1634. **10.** Brod M, Pohlman B, Højbjerg L, Adalsteinsson JE, Rasmussen MH. Impact of adult growth hormone deficiency on daily functioning and well-being. *BMC Res Notes.* 2014;7:813. doi:10.1186/1756-0500-7-813. **11.** Carroll PV, Christ ER, Bengtsson BÅ, et al; and the members of the Growth Hormone Research Society Scientific Committee. Growth hormone deficiency in adulthood and the effects of hormone replacement: a review. *J Clin Endocrinol Metab.* 1998;83(2):382-395. **12.** Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2016;101(11):3888-3921. **13.** Kreber LA, Griesbach GS, Ashley MJ. Detection of growth hormone deficiency in adults with chronic traumatic brain injury. *J Neurotrauma.* 2016;33(17):1607-1613.



Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2020 Novo Nordisk All rights reserved. US20GH00029 July 2020